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Percutaneous Transluminal Angioplasty
of Renal Artery Fibromuscular Dysplasia:
Mid-term Results
Objective: To evaluate mid-term imaging, clinical follow-up, and restenosis
rates from patients that had undergone percutaneous transluminal renal artery
angioplasty (PTRA) for symptomatic renal artery fibromuscular dysplasia (FMD).
Materials and Methods: Between March 1999 and July 2006, 16 consecutive
renal artery FMD patients underwent PTRA for poorly controlled hypertension.
The patients were enrolled into this retrospective study after receiving 19 primary
and four secondary PTRAs in 19 renal artery segments. Follow-up monitoring of
blood pressure, use of antihypertensive medication, and the serum creatinine
level after PTRA were assessed at 1, 3, 6, 9, 12 months, and each following year.
The degree of restenosis was evaluated with computed tomographic angiogra-
phy (CTA) after PTRA at 6, 12 months, and every year if possible. Technical and
clinical success rates for the treatment of FMD, and restenosis rates for the renal
artery were evaluated.
Results: The technical success rate for primary PTRA was 79% (15/19) and
the complication rate was 16% (3/19). Hypertension improved in 80% (12/15) of
the patients after four weeks follow-up, and was finally cured or improved in 93%
(14/15) during the mean follow-up period of 23.6 months. There was a cumulative
22% (4/18) restenosis rate during the follow-up period. All of the patients were
treated with a second PTRA without complications and all of the patients were
cured of hypertension after the second PTRA.
Conclusion: Percutaneous transluminal renal artery angioplasty for clinically
symptomatic renal FMD is technically and clinically successful and safe to per-
form. For all patients with restenosis, there was a good response after undergo-
ing a second PTRA.
ibromuscular dysplasia (FMD) accounts for 10% of all cases of renal
artery stenosis (1). FMD is usually seen in young women and can
progress to uncontrolled hypertension, but it only rarely progresses to
complete occlusion of the renal artery (2). Renovascular hypertension caused by FMD
is one of the most common curable forms of hypertension (3 5).
Surgical reconstruction has been the accepted standard of therapy for renal artery
FMD (6). Recently, percutaneous transluminal renal artery angioplasty (PTRA), with
or without stent placement, has become the preferred choice for correcting sympto-
matic renal FMD as it is less invasive than surgical reconstruction (7, 8).
Several reports have described the short-term technical and clinical success of PTRA
for renal artery FMD (9 11). However, few reports have described mid- to long-term
durability and clinical success of PTRA. The purpose of this retrospective study was to
evaluate the mid-term imaging and clinical follow-up of blood pressure responses and
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Frestenosis rates from patients that had previously
undergone PTRA for symptomatic renal artery FMD.
MATERIALS AND METHODS
Patients
We obtained approval from the institutional review
board of our hospital for a retrospective review of patient
medical and imaging records, but the institutional review
board did not require informed consent. Written consent
for the procedure from all patients was obtained after a
discussion about the advantages and risks of the procedure
(12).
From March 1999 through July 2006, 16 consecutive
renal artery FMD patients underwent PTRA for poorly
controlled hypertension (a systolic blood pressure of 140
mmHg or above and/or a diastolic blood pressure of 90
mmHg or above on antihypertensive medication with
more than two drugs) (13). The patients consisted of eight
men and eight women between the ages of seven and 61
years (mean age 32.5 years). The patients underwent 19
primary and four secondary PTRA operations for 19 renal
artery segments. Five patients had decreased kidney size
and one patient had a history of acute renal failure and
diabetes mellitus.
The diagnosis of renal artery stenosis due to FMD was
based on angiographic appearance as proposed by
McCormack et al. (14) and clinical aspects. There was no
intimal thickening or calcification in the aorta, but angiog-
raphy revealed a non-ostial localization of stenosis with
serum ESR and CRP values within the normal range
through the entire follow-up period (15). Patients were
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Fig. 1. Stenosis shapes of renal artery fibromuscular
dysplasia. 
A. focal stenosis
B. beaded-multifocal stenosis
C. diffuse segmental stenosis.
Cevaluated by computed tomographic angiography (CTA)
or MRI to confirm the diagnosis of renal artery stenosis.
Follow-up Assessment and Definition
After PTRA, patients stayed in the hospital for at least
three days for blood pressure and renal function monitor-
ing. During this time, antihypertensive treatment was
adjusted according to the clinical needs of each patient.
Patients were then discharged and began a follow-up
period that included blood pressure monitoring, physical
examinations, and if necessary, CTA follow-up.
Follow-up monitoring of blood pressure, antihyperten-
sive medication, and the serum creatinine level were
assessed at 1, 3, 6, 9, 12 months, and every year after
PTRA. The degree of restenosis was evaluated with CTA
after PTRA at 6, 12 months, and every year, if possible.
Clinical follow-up ranged from one to 60 months (mean,
23.6 months) and imaging follow-up with CTA ranged
from three to 40 months (mean, 18.3 months). The techni-
cal and clinical success rate, and the restenosis rates for the
renal artery were evaluated. One of the 16 patients
included in this study was unavailable for follow-up. CTA
follow-up data was available from 12 patients; this
information was not available from the three most recent
patients.
After PTRA, blood pressure response was described
according to the American Heart Association (AHA)
guidelines (16). Hypertension was defined as a systolic
blood pressure greater than 140 mmHg or a diastolic blood
pressure greater than 90 mmHg. A cure was defined as a
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Fig. 2. A 29-year-old woman with a focal stenosis in the midportion of the left renal artery. 
A. Angiography shows a focal stenosis (arrow). 
B. There is an approximate 40% residual stenosis (arrow) after percutaneous transluminal renal artery angioplasty. 
C. Six months later, CT angiography shows no interval change in the residual stenosis (arrow).
D. Twenty-six months later, CT angiography shows no interval change in the residual stenosis (arrow).
CD
ABsystolic blood pressure less than 140 mmHg and a diastolic
blood pressure less than 90 mmHg without the use of
antihypertensive medication. Improved status was defined
as a diastolic blood pressure less than 90 mmHg and/or a
systolic blood pressure less than 140 mmHg without an
increase in the dosage of medication. Improvement could
also be defined as a reduction in diastolic blood pressure
by at least 15 mmHg without increased use of medication.
No change was defined as no change or the inability to
meet the above criteria for cure and improvement. Patients
were seen to have a benefit or cure if improvement in the
blood pressure status was observed. An elevated serum
creatinine level was defined as > 1.5 mg/dL.
By analyzing the angiographic findings for the renal
artery, focal stenosis was defined as focal, concentric
lesions within 0.5 cm in length. Beaded type stenosis was
defined as multifocal stenosis resembling a string of beads.
Diffuse segmental type stenosis was defined as a long,
smooth narrowing lesion. Ostial lesions were defined as
lesions within 0.5 cm of the renal artery orifice. Proximal
lesions were defined as lesions within 1 cm of the renal
artery orifice. Middle lesions were defined as lesions not
ostial or proximal, but appearing before any branching of
the main renal artery. Distal lesions involved the branching
renal artery.
Technical success was defined as a residual stenosis of
less than 30%. Failure was defined as a residual stenosis of
greater than 30% or lesion that could not be crossed or
dilated. Restenosis was defined as a stenosis greater than
50%, as demonstrated by CTA or angiography during
follow-up.
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Fig. 3. A 26-year-old-man with a beaded stenosis in the midportion of the right renal artery. 
A. Angiography shows a beaded stenosis of a renal artery (arrow). 
B, C. Follow-up CT angiography and angiography show restenosis (arrows) of the renal artery after 28 months. At that time, there was a
sudden elevation of blood pressure. 
D. After a second percutaneous transluminal renal artery angioplasty, selective right renal angiography shows a successfully dilated
renal artery. Clinical cure was achieved after performing a successful second percutaneous transluminal renal artery angioplasty.
CD
ABAngioplasty
In general, angiographic analysis was performed via a
femoral approach. Balloon angioplasty was performed
with systemic heparinization (80 U/kg IV), a 0.035 inch
guidewire (Terumo Medical Corporation, Tokyo, Japan) or
an 180/350 cm microwire (SV-5, Cordis Endovascular,
Miami Lakes, FL), guding catheter (RDC, Cordis
Endovascular), 3 6 mm balloon expandible catheter
(Genesis, Cordis Endovascular) and Genesis stent (Cordis
Endovascular). A cutting balloon was used in one renal
artery for residual stenosis after conventional angioplasty.
The balloon diameter was selected to be equal to or
slightly larger than the diameter of the renal artery that
was estimated on an angiogram. Stents were inserted in
three patients that had complications and one patient with
residual stenosis after primary PTRA.
RESULTS
Out of 16 patients, three patients that had bilateral renal
artery stenosis underwent bilateral PTRA procedures in
the same setting. Lesion distribution in the renal artery was
proximal for four cases, middle for 12 cases, and distal for
one case. Two lesions involved middle and distal vessels
simultaneously. Nine lesions had focal stenosis, five lesions
had beaded stenosis, four lesions had diffuse segmental
stenosis, and one lesion had focal and segmental stenosis as
seen by selective angiography (Fig. 1). Technical success
was seen for 79% (15/19) of the PTRAs. One patient had a
residual stenosis after a primary PTRA with no clinical
change during the 26 months of follow-up (Fig. 2), and
three other patients had complications (3/19, 16%) associ-
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Fig. 4. A 29 year-old-woman with a beaded stenosis in the midportion of the right renal artery. 
A. Angiography shows a beaded stenosis (arrow). 
B, C. Restenosis (arrows) of the renal artery was noted on CT angiography and angiography without clinical change after 12 months. 
D. After a second percutaneous transluminal renal artery angioplasty, selective right renal angiography shows successfully dilated renal
artery. Clinical cure was achieved after performing a successful second percutaneous transluminal renal artery angioplasty.
CD
ABated with the primary PTRA: one patient suffered rupture
of the renal artery, and two patients had flow-compromis-
ing dissection. A stent was inserted for each case of arterial
rupture and dissection without complication. In one
patient, a cutting balloon was used for residual renal artery
stenosis after PTRA. The cutting balloon ruptured a renal
artery. We inserted a balloon and inflated it with low
pressure for 5 minutes. This caused near total occlusion of
the renal artery. We inserted a self-expandable stent.
Fortunately, final angiography and follow-up CT showed
that the renal artery to have no leakage of contrast
medium. One patient already had a flow-compromising
dissection associated with renal artery FMD before the
procedure. A stent was also inserted without complica-
tions. There were no serious adverse events associated
with the interventions and no periprocedural mortalities.
Clinical Success and Restenosis Rates
In this study, improvement was seen for 12 of 15
patients (80%), and no change of blood pressure control
was observed for three of 15 patients (20%) after four
weeks clinical follow-up (one patient was unavailable for
follow-up). One of the improved patients seen to be cured
of high blood pressure after 12 months as seen by clinical
follow-up. There were four patients (4/18, 22%) with
restenosis as confirmed by follow-up CTA, each at 6, 7, 14
and 28 months later. Two of the patients showed aggrava-
tion of blood pressure control during clinical follow-up
(Fig. 3). All four restenotic lesions were treated with a
second PTRA operation without complications and all of
these patients were subsequently cured of hypertension
(Fig. 4).
During the mean clinical follow-up period of 23.6
months (range, 1 to 60 months), six of 15 patients were
finally cured of arterial hypertension and eight patients had
improved blood pressure control. Clinical benefit
(improved or cured hypertension) was seen for 14/15
(93%) patients overall.
There were two patients with impaired renal function (a
serum creatinine level > 1.5 mg/dL) before PTRA. The
serum creatinine level decreased with no further deteriora-
tion in these patients after PTRA.
DISCUSSION
This study evaluated outcomes for PTRA in hypertensive
patients with renal artery FMD. Technical success for
PTRA was seen in 79% (15/19) of all patients studied.
Clinical success with improvement/cure of arterial
hypertension was 80% (12/15) through the first one
month, and 93% (14/15) through the second year of the
follow-up period. There were four patients (4/18, 22%)
with restenosis, as confirmed by follow-up CTA (Fig. 3).
All four restenotic lesions were treated with a second
PTRA procedure without complications and all of these
patients were cured of hypertension after the second
PTRA. Few studies have focused solely on patients with
FMD (8, 17). A study by Bonelli et al., the largest subset
analysis described to date, reported on 105 patients treated
with PTRA for renal artery FMD over a 14-year period
(18). Of these patients, 63% had improved blood pressure
levels and about 50% maintained the same blood pressure
for eight years (18). Even though the number of patients
was small and the follow-up period was short, our study
had a better outcome with a 93% clinical benefit through
the mean follow-up period of almost two years.
PTRA is often misunderstood to be a cure for renal
artery FMD. However, this study shows clinical improve-
ment is more common than clinical cure. Thus following
PTRA, it is much more likely that one is able to reduce the
number of medications needed than to replace them
completely. In our study, a 40% (6/15) cure rate and a
53% (8/15) of improvement rate was recorded during the
follow-up period. Klinge et al. reported a cure rate of 38%
(18/47), and improved blood pressure control in 55%
(26/47) of patients after six months (19). Mounier-Vehier
et al. used CTA to evaluate renal length, cortical thickness,
cortical area, and medullary length in 20 patients with
unilateral FMD (15). These investigators reported a cure
rate of 25% (5/20), and improvement in other patients. In
this study, despite successful revascularization and
stabilization, there was no recovery from renal atrophy.
This could partially explain the persistence of hypertension
in 15 of 20 patients (15).
Fewer studies have documented the effects of PTRA on
renal function in patients with FMD (13). Our data on
renal function in patients with FMD is limited. In our
study, there were two patients with serum creatinine levels
above 1.5 mg/dL before PTRA. The level of serum creati-
nine decreased or stabilized in these patients after PTRA.
Birrer et al. reported on five patients with elevated serum
creatinine levels, and all improved after PTRA. These five
patients began with impaired renal function, but none
progressed to end-stage renal failure over the 12-month
follow-up period (17).
One patient in our study was a 20-year-old man that had
a rupture of the renal artery after cutting balloon
angioplasty. A stent was deployed soon afterwards. After
one month, there was improvement in his blood pressure.
Oguzkurt et al. reported a case of arterial rupture with
cutting balloon PTA in renal artery FMD. These investiga-
tors stated that arterial involvement in FMD causes
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thinning of the arterial wall, probably making it susceptible
to rupture with cutting balloon PTA (20).
There were four patients with restenosis during follow-
up. All of the patients underwent a successful secondary
PTRA without complications, and the patients were cured
of renal artery hypertension. We found that performing a
secondary PTRA for recurring stenosis of renal arteries
shows good technical and clinical outcomes.
There are some limitations to be considered in this study.
First, as this study was a retrospective study, we had
variable imaging and clinical follow-up periods for each
patient. Therefore, the statistical analysis was not shown to
be significant by the Kaplan-Meier method. Second, due to
the small sample size, it was difficult to calculate primary
and secondary renal artery patency rates after PTRA.
Third, due to the relatively short mean follow-up period,
we could not evaluate the long-term effects of PTRA in
these symptomatic FMD patients.
In conclusion, PTRA for clinically symptomatic renal
FMD is technically and clinically successful and safe to
perform. For all patients with restenosis, there was a good
response to a secondary PTRA in this study. However, a
longer follow-up period is necessary for the evaluation of
the long-term effects of PTRA.
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